MarginsXMarginsX
Home › Markets › Health Care › CHRS

Coherus Oncology Inc. (CHRS)

CHRS trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.5059
-3.73% on the day
Market cap
$78.2M
Micro cap
Revenue · 2025
$42.2M
+59.8% on 2024
Net income · 2025
$168.0M
398.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/0001104659-26-025308-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCHRS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2014
SEC CIK0001512762
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$42.2M
Net income$168.0M
Operating income-$181.1M
Net margin398.4%
Operating margin-429.5%
Revenue growth+59.8%
Cash$88.9M
Total assets$258.3M
P/E (computed)0.5×
P/S (computed)1.9×

Warning signs

Cash runway
3.7 months
$53.5M cash at September 30, 2026
Share count, 1 year
+27.9%
2025-10-31 to 2026-10-31 · +38.8% over 3 years
Going-concern doubt
Yes
10-Q filed November 9, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Our expected future operating losses and negative operating cash flows, together with our need for additional funding to support planned operations, raise substantial doubt about our ability to continue as a going concern."
10-Q 2026-11-09
Cash and burn$53.5M cash; operating cash flow -$43.4M a quarter.Report 2026-09-30
Shares outstanding154,538,277 (2026-10-31); 120,871,013 a year earlier; 111,364,152 three years earlier.Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 4 424B5 takedowns, 4 at the marketLatest 2026-08-28
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Francisco, California, United States; changed auditors 1 time in 24 months8-K 4.01 2026-06-15
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$14.3M-$39.3M-$34.0M$53.5MNo debt tags$53.6M10-Q 2026-11-09
Q2 2026
2026-06-30
$14.3M-$20.6M-$62.1M$82.9MNo debt tags$50.9M10-Q 2026-08-05
Q1 2026
2026-03-31
$12.3M-$38.3M-$57.9M$115.2MNo debt tags$46.9M10-Q 2026-05-11
Q4 2025
2025-12-31
$12.7M-$37.6M-$19.7M$88.9MNo debt tags$42.2M10-K 2026-03-09
Q3 2025
2025-09-30
$11.6M-$35.5M-$46.3M$103.4MNo debt tags$37.2M10-Q 2026-11-09
Q2 2025
2025-06-30
$10.3M$297.8M-$46.6M$216.9MNo debt tags$31.6M10-Q 2026-08-05
Q1 2025
2025-03-31
$7.6M-$56.6M-$25.8M$82.4MNo debt tags$31.7M10-Q 2026-05-11
Q4 2024
2024-12-31
$7.7M-$50.7M$28.6M$126.0MNo debt tags$26.4M10-K 2026-03-09

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-08-28
Latest annual report10-K2026-03-09
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-05-28

Source: SEC EDGAR submissions feed, 923 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-31.7%
1 month-50.8%
3 months-53.9%
Year to date-63.0%
1 year-58.3%
From 52-week high-79.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
TNYATenaya Therapeutics Inc.$0.3336-4.47%$76.0M
AVXLAnavex Life Sciences Corp.$0.8176-12.42%$75.8M
BDTXBlack Diamond Therapeutics Inc.$1.53+4.08%$87.9M
NMRANeumora Therapeutics Inc.$0.3695-13.85%$69.4M
CRDFCardiff Oncology Inc.$0.8477+16.75%$65.9M
ATRAAtara Biotherapeutics Inc.$6.40-16.88%$65.2M
CSBRChampions Oncology Inc.$4.68-0.53%$65.1M
OTLKOutlook Therapeutics Inc.$0.3960-4.12%$96.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier